Inactivated Vaccines Market Analysis 2024-2033 Size, Top Segments, Leading Trends And Forecast

The Business Research Company has recently revised its global market reports, now incorporating the most current data for 2024 along with projections extending up to 2033.

Inactivated Vaccines Global Market Report 2024 by The Business Research Company offers comprehensive market insights, empowering businesses with a competitive edge. It includes detailed estimates for numerous segments and sub-segments, providing valuable strategic guidance.

The Market Size Is Expected To Reach $7.33 billion In 2028 At A CAGR Of 4.3% :

The inactivated vaccines market size has grown steadily in recent years. It will grow from $5.95 billion in 2023 to $6.19 billion in 2024 at a compound annual growth rate (CAGR) of 4.2%. The growth in the historic period can be attributed to polio eradication efforts, influenza vaccination programs, emerging infectious diseases, regulatory approvals.

The inactivated vaccines market size is expected to see steady growth in the next few years. It will grow to $7.33 billion in 2028 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to pandemic preparedness, expanding vaccine coverage, biomanufacturing advancements, health equity initiatives. Major trends in the forecast period include mrna vaccine platforms, combination vaccines, thermostable vaccines, digital vaccine passports.

Request A Sample Of This Report -
https://www.thebusinessresearchcompany.com/sample.aspx?id=13018&type=smp

Inactivated Vaccines Market Major Segments
The inactivated vaccines market covered in this report is segmented -
1) By Type: Viral Vaccine; Bacterial Vaccine
2) By Method Of Inactivation: Solvent Detergent; Radiation; pH Concentration; Heat Inactivation; Other Methods Of Inactivation
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Other Distribution Channels

Key Driver - Rising Prevalence Of Infectious Diseases Boost Inactivated Vaccines Market In Combating Diseases

The increasing prevalence of infectious diseases is expected to propel the growth of the inactivated vaccine market going forward. Infectious diseases are illnesses caused by pathogens such as bacteria, viruses, fungi, or parasites that can spread from person to person, resulting in a wide range of symptoms and health complications. Tuberculosis is one type of infectious disease. Inactivated vaccines use non-living pathogens to stimulate an immune response, effectively preventing diseases like polio, hepatitis A and influenza. For instance, in October 2022, according to the Global Tuberculosis Report published by the World Health Organization, a Switzerland-based global health agency, there will be a 4.5% increase in the global incidence of tuberculosis from the projected 10.1 million cases to 10.6 million cases in 2021. The majority of tuberculosis cases were reported in the Southeast Asia region, accounting for 45% of the total, followed by Africa with 23% of the cases. Therefore, the increasing prevalence of infectious diseases is driving the growth of the inactivated vaccine market.

Customise This Report As Per Your Requirements -
https://www.thebusinessresearchcompany.com/Customise?id=13018&type=smp

Prominent Trend - Innovative Advancements In Inactivated Vaccines By Leading Companies For Disease Prevention

Major companies operating in the inactivated vaccines market are introducing innovative and advanced inactivated vaccines to sustain their position in the market. An inactivated vaccine contains inactivated virus particles, bacteria, or other pathogens that have been developed in culture and subsequently killed to destroy disease-producing ability. For instance, in January 2022, GSK plc, a UK-based pharmaceutical and biotechnology company, released a new inactivated vaccination to aid with shingles protection named Shingrix to prevent shingles (Herpes zoster). Shingrix is a non-live, recombinant subunit adjuvanted vaccination administered intramuscularly in two doses. The vaccine's initial indication was for individuals 50 years and older. It has lately been expanded to cover persons 18 and older at a higher risk of developing shingles due to immunodeficiency or immunosuppression caused by a known illness or treatment.

Inactivated Vaccines Market Players
Major players in the inactivated vaccines market are Pfizer Inc., Johnson & Johnson Services Inc., Sinopharm Group Co. Ltd., Merck & Co. Inc., Sanofi S.A., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Zydus Lifesciences Ltd., Sinovac Biotech Ltd., Biological E Limited, Hualan Biological Engineering Inc., CanSino Biologics Inc., Shenzhen Kangtai Biological Products Co. Ltd., Serum Institute of India Pvt. Ltd., Beijing Tiatan Biological Products Co. Ltd., Valneva SE, Bavarian Nordic A/S., Beijing Minhai Biotechnology Co. Ltd., Bharat Biotech International Limited, Panacea Biotec Ltd., Sinergium Biotech SA, Bharat Immunologicals and Biologicals Corporation Limited, Haffkine Biopharmaceutical Corporation Limited, Incepta Vaccine Ltd., Changchun BCHT Biotechnology Co. Ltd., .

View The Full Report Here -
https://www.thebusinessresearchcompany.com/report/inactivated-vaccines-global-market-report

Largest And Fastest Growing Region In The Market
North America was the largest region in the inactivated vaccines market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in inactivated vaccines market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Inactivated Vaccines Market Report Structure
3. Inactivated Vaccines Market Trends And Strategies
4. Inactivated Vaccines Market - Macro Economic Scenario
5. Inactivated Vaccines Market Size And Growth
…..
27. Inactivated Vaccines Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.